<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.thepeptidenewsroom.com/mots-c-evidence-is-almost-entirely-preclinical-but-the-peptide-is-already-availa/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-05</news:publication_date>
      <news:title>MOTS-c Evidence Is Almost Entirely Preclinical, But the Peptide Is Already Available by Prescription</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.thepeptidenewsroom.com/indexbox-forecasts-8-5-growth-for-vegan-collagen-peptides-but-names-no-trials/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-05</news:publication_date>
      <news:title>IndexBox Forecasts 8.5% Growth for Vegan Collagen Peptides, But Names No Trials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.thepeptidenewsroom.com/indexbox-forecasts-5-8-annual-growth-for-collagen-tablets-but-claims-rules-could/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-05</news:publication_date>
      <news:title>IndexBox Forecasts 5.8% Annual Growth for Collagen Tablets, But Claims Rules Could Tighten</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.thepeptidenewsroom.com/australia-approves-first-wegovy-tablet-but-the-pill-comes-with-daily-rules/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-05</news:publication_date>
      <news:title>Australia Approves First Wegovy Tablet, But the Pill Comes With Daily Rules</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.thepeptidenewsroom.com/rfk-jr-opens-six-peptides-to-compounding-pharmacies-but-fda-reviewers-objected/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-04</news:publication_date>
      <news:title>RFK Jr. Opens Six Peptides to Compounding Pharmacies, But FDA Reviewers Objected</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.thepeptidenewsroom.com/review-finds-no-class-wide-eye-toxicity-from-glp-1-drugs-but-flags-two-retinal-s/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-04</news:publication_date>
      <news:title>Review Finds No Class-Wide Eye Toxicity From GLP-1 Drugs, But Flags Two Retinal Signals</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.thepeptidenewsroom.com/hhs-draft-policy-names-six-peptides-for-compounding-but-it-is-not-fda-approval/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-04</news:publication_date>
      <news:title>HHS Draft Policy Names Six Peptides for Compounding, But It Is Not FDA Approval</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.thepeptidenewsroom.com/ascletis-will-show-preclinical-data-on-oral-gipr-agonist-and-triple-peptide-agon/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-04</news:publication_date>
      <news:title>Ascletis Will Show Preclinical Data on Oral GIPR Agonist and Triple Peptide Agonist at ObesityWeek</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.thepeptidenewsroom.com/ai-found-peptide-cut-food-intake-in-mice-and-minipigs-but-human-trials-have-not-/</loc>
    <news:news>
      <news:publication>
        <news:name>The Peptide Newsroom</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-04</news:publication_date>
      <news:title>AI-Found Peptide Cut Food Intake in Mice and Minipigs, But Human Trials Have Not Started</news:title>
    </news:news>
  </url>
</urlset>